PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS

PYRIDIN-2 -YL-AMINO-I, 2, 4 -THIADIAZOLE DERIVATIVES AS GLUCOKINASE ACTIVATORS FOR THE TREATMENT OF DIABETES MELLITUS

Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JAY BRADFORD FELL, MARK JOSEPH CHICARELLI, ELI M. WALLACE, RONALD JAY HINKLIN, TIMOTHY M. TURNER, INDRANI W. GUNAWARDANA, KEVIN RONALD CONDROSKI, JOHN P. FISCHER, STEVEN ARMEN BOYD, THOMAS DANIEL AICHER, AJAY SINGH
Format: Patent
Sprache:eng ; spa
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting glycemia), as well as other diseases and disorders such as those discussed herein. S proporcionan compuestos de la fórmula (I): (ver fórmula (I)) en donde R2, R3, R13, L y D2 son como se define en la descripción, los cuales son útiles en el tratamiento y/o prevención de enfermedades o trastornos mediados por niveles deficientes de actividad glucocinasa o los cuales pueden ser tratados al activar glucocinasa, incluyendo, pero no limitados a, diabetes mellitus, tolerancia a glucosa alterada, IFG (glucosa en ayunas alterada) e IGF (glucemia en ayunas alterada), asi como otras enfermedades y trastornos tales como aquellos descritos en la presente.